EarningsNovo Nordisk Crushes Q1 Forecasts—But Slashes 2025 Outlook Anyway Despite record-breaking Q1 earnings from Wegovy and Ozempic sales, Novo Nordisk mysteriously slashes its 2025 outlook. What’s really going on?Richard's Trades TeamMay 8, 2025